Passage Bio

Developing AAV gene therapies for the treatment of genetic central nervous system diseases

Passage Bio is a gene therapy company focused on the discovery and development of genetic medicines for monogenic central nervous system diseases. Passage was founded on adeno-associated virus (AAV) technologies developed in the laboratory of Dr. James Wilson at the University of Pennsylvania.

Year of Investment
2018
Strategy
Life Sciences
Location
Philadelphia, Pennsylvania